GROWTH
Top line accelerating.
+5.4% YoY versus +2.7% prior. 3y CAGR +4.4%.
+5.4%
AptarGroup, Inc. ATR
Healthcare · Market Cap: $7.5B
$120.32▲ 0.33 (0.28%)
Fundamentals as of 2026-03-31
We use cookies
MainRatios uses cookies for essential site functions. With your consent, we also use analytics cookies including session replay sampling (PostHog, Google Analytics) and advertising cookies (Google AdSense). You can reject non-essential cookies, including the "sale" or sharing of personal information under CCPA, and you may withdraw consent at any time (GDPR). See our Privacy Policy for details.
Healthcare · Market Cap: $7.5B
Fundamentals as of 2026-03-31
All analysis on this page is for educational purposes only and does not constitute financial advice. Fair values are model-based estimates. Always do your own research.
1 of 2 legendary models say BUY ATR — but Peter Lynch disagrees.
What would legendary investors pay for ATR?
These figures are not quotes or opinions from Buffett, Graham, Lynch or the other investors. They are our own estimates, computed by applying the intrinsic-value formulas each investor is known for to this company’s financials.
For educational purposes only. Not a recommendation to buy or sell securities.
+5.4% YoY versus +2.7% prior. 3y CAGR +4.4%.
+5.4%Net margin 10.4% versus 10.5% prior (−0.1pp). Operating 13.5%.
10.4%P/E 19.4x — 35% below the 5y median of 29.7x. Forward 21.8x signals EPS contraction next year.
19.4xThe Question
Bottom line: ATR splits the legendary models — 1 BUY, 0 HOLD, 1 AVOID, but earns a C sector grade (58/100) in Healthcare. Whether the premium is justified depends on which lens you trust. Drill into the valuation breakdown and sector ranking for the full picture.
AptarGroup, Inc.'s ROE and debt-to-equity are non-meaningful — large accumulated buybacks have driven stockholders' equity below zero, so the ratio denominators are uninterpretable. Operating margin and free cash flow are the better lenses here.
Financial story
AptarGroup, Inc.'s ROE and debt-to-equity are non-meaningful — large accumulated buybacks have driven stockholders' equity below zero, so the ratio denominators are uninterpretable. Operating margin and free cash flow are the better lenses here.
1 of 2 legendary investor models rate ATR a BUY. Fair value estimates and full investor breakdown are in the valuation tab.
Average fair value across qualifying models: $245. See the per-investor fair-value table in the valuation tab.
ATR trades at 20.4x earnings. Sector context and per-investor signals are in the valuation tab.
ATR and BIO differ on P/E, ROE, and revenue growth. See the full ATR vs BIO compare matrix.
Buffett and Lynch evaluate ATR against their respective frameworks. Per-model fair value and reasoning are in the valuation tab.
ATR's P/E ratio is 20.4x. 5-year P/E history is in the financials tab.
How does ATR compare?
See exactly where ATR ranks
Sign in to unlock the full sector ranking — free.
Sign in to see the rankingATR sits at #24 in Healthcare with a C grade (58/100).
